▼ -0.69% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Intersect ENT in the last 3 months. The average price target is $23.00, with a high forecast of $32.00 and a low forecast of $10.00. The average price target represents a -0.69% upside from the last price of $23.16.
The current consensus among 8 contributing investment analysts is to hold stock in Intersect ENT. This rating has held steady since May 2019, when it changed from a Buy consensus rating.
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.